Free Trial

MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

$39.49
-0.68 (-1.69%)
(As of 06/18/2024 ET)

MoonLake Immunotherapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$74.46
88.56% Upside
High Forecast$100.00
Average Forecast$74.46
Low Forecast$56.00
TypeCurrent Forecast
6/19/23 to 6/18/24
1 Month Ago
5/20/23 to 5/19/24
3 Months Ago
3/21/23 to 3/20/24
1 Year Ago
6/19/22 to 6/19/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
11 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$74.46$74.46$73.42$25.63
Forecasted Upside88.56% Upside51.13% Upside44.72% Upside40.99% Upside
Get MoonLake Immunotherapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.

MLTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MLTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MoonLake Immunotherapeutics Stock vs. The Competition

TypeMoonLake ImmunotherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.70
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside88.56% Upside1,068.17% Upside11.30% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/11/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$100.00 ➝ $100.00+138.32%
6/10/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$66.00 ➝ $66.00+57.18%
4/2/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$62.00+27.57%
3/13/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$92.00+84.85%
2/26/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$92.00+76.52%
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$77.00+23.20%
12/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$66.00 ➝ $69.00+14.56%
12/8/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$72.00+30.32%
11/15/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$70.00 ➝ $77.00+90.83%
11/8/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$78.00+94.51%
9/14/2023Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
9/12/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$41.00 ➝ $59.00+12.12%
6/27/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$36.00 ➝ $68.00+47.99%
6/26/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$28.00 ➝ $56.00+21.87%
5/4/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates
12/21/2022Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Katkhuda
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
11/11/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$16.00+93.00%
8/25/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Thomas Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$17.00+88.68%
7/7/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:12 PM ET.

MLTX Forecast - Frequently Asked Questions

What is MoonLake Immunotherapeutics's stock forecast and purchase recommendation?

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for MoonLake Immunotherapeutics is $74.46, with a high forecast of $100.00 and a low forecast of $56.00. The consensus rating for MoonLake Immunotherapeutics stock is Moderate Buy based on the current 3 hold ratings and 9 buy ratings for MLTX. Learn more on MLTX's analyst rating history.

Do Wall Street analysts like MoonLake Immunotherapeutics more than its competitors?

Analysts like MoonLake Immunotherapeutics more than other "medical" companies. The consensus rating score for MoonLake Immunotherapeutics is 2.75 while the average consensus rating score for "medical" companies is 2.70. Learn more on how MLTX compares to other companies.

Does MoonLake Immunotherapeutics's stock price have much upside?

According to analysts, MoonLake Immunotherapeutics's stock has a predicted upside of 51.08% based on their 12-month stock forecasts.

What analysts cover MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics has been rated by research analysts at HC Wainwright, Needham & Company LLC, and The Goldman Sachs Group in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:MLTX) was last updated on 6/18/2024 by MarketBeat.com Staff

From Our Partners